The University of Chicago Header Logo

Connection

Michael Charlton to Liver Transplantation

Back to Details
This is a "connection" page, showing publications Michael Charlton has written about Liver Transplantation.
Michael Charlton
Connection Strength
20.351
Liver Transplantation
  1. Living Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes, and Factors Associated With Outcomes. Liver Transpl. 2021 07; 27(7):1019-1031.
    View in: PubMed
    Score: 0.448
  2. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation. 2021 06 01; 105(6):1285-1290.
    View in: PubMed
    Score: 0.446
  3. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. J Gastroenterol. 2020 Jul; 55(7):722-730.
    View in: PubMed
    Score: 0.413
  4. Nonalcoholic Steatohepatitis After Liver Transplantation. Liver Transpl. 2020 01; 26(1):141-159.
    View in: PubMed
    Score: 0.402
  5. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation. 2019 04; 103(4):733-746.
    View in: PubMed
    Score: 0.384
  6. Liver Transplantation for Nonalcoholic Steatohepatitis: New Evidence of a Profound Increase Across Age Cohorts. Transplantation. 2019 01; 103(1):1-2.
    View in: PubMed
    Score: 0.378
  7. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 05; 102(5):727-743.
    View in: PubMed
    Score: 0.360
  8. Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. Transplantation. 2017 12; 101(12):2873-2882.
    View in: PubMed
    Score: 0.350
  9. Predictors of Cardiovascular Events After Liver Transplantation. Clin Liver Dis. 2017 05; 21(2):367-379.
    View in: PubMed
    Score: 0.332
  10. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 04; 152(5):1090-1099.e1.
    View in: PubMed
    Score: 0.329
  11. Roadmap for improving patient and graft survival in the next 10 years. Liver Transpl. 2016 11; 22(S1):71-78.
    View in: PubMed
    Score: 0.325
  12. Alcoholic Liver Disease and Liver Transplantation. Clin Liver Dis. 2016 08; 20(3):521-34.
    View in: PubMed
    Score: 0.319
  13. Nonalcoholic Fatty Liver Disease and Liver Transplantation. Clin Liver Dis. 2016 May; 20(2):403-17.
    View in: PubMed
    Score: 0.314
  14. Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. Gastroenterology. 2016 06; 150(8):1849-62.
    View in: PubMed
    Score: 0.311
  15. Usefulness of Liver Transplantation in the Elderly: The Converging Impact of Risk and Benefit. Gastroenterology. 2016 Feb; 150(2):306-9.
    View in: PubMed
    Score: 0.306
  16. Response to Fibrosis progression in patients treated for hepatitis C recurrence. Liver Int. 2015 Dec; 35(12):2625.
    View in: PubMed
    Score: 0.305
  17. Lack of Survival Benefit Following Liver Transplantation With MELD Exception Points for Hepatocellular Carcinoma: Beyond the Unblinding of Lady Justice. Gastroenterology. 2015 Sep; 149(3):531-4.
    View in: PubMed
    Score: 0.298
  18. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
    View in: PubMed
    Score: 0.296
  19. Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful? Liver Int. 2015 Jan; 35(1):9-11.
    View in: PubMed
    Score: 0.286
  20. Chronic kidney disease (CKD) and NAFLD: time for awareness and screening. J Hepatol. 2015 Apr; 62(4):983-4.
    View in: PubMed
    Score: 0.285
  21. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
    View in: PubMed
    Score: 0.281
  22. Improving long-term outcomes after liver transplantation. Clin Liver Dis. 2014 Aug; 18(3):717-30.
    View in: PubMed
    Score: 0.278
  23. Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events. Liver Transpl. 2014 Jul; 20(7):791-7.
    View in: PubMed
    Score: 0.274
  24. Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl. 2013 Dec; 19(12):1311-7.
    View in: PubMed
    Score: 0.265
  25. How important is acute cellular rejection? Liver Transpl. 2013 Nov; 19 Suppl 2:S9-13.
    View in: PubMed
    Score: 0.264
  26. Victory and defeat at Heraclea - treating hepatitis C infection following liver transplantation with telaprevir and boceprevir. J Hepatol. 2014 Jan; 60(1):6-8.
    View in: PubMed
    Score: 0.263
  27. The lethal and enduring inequity of deceased donor liver allocation policy for hepatocellular carcinoma in the United States. Am J Transplant. 2013 Nov; 13(11):2794-6.
    View in: PubMed
    Score: 0.262
  28. Sirolimus as a calcineurin inhibitor- and renal-sparing agent: all good things come to those who wait versus spare the nephron, spoil the patient. Liver Transpl. 2013 Aug; 19(8):787-9.
    View in: PubMed
    Score: 0.259
  29. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant. 2013 Sep; 13(9):2450-7.
    View in: PubMed
    Score: 0.259
  30. Preserving flow in liver transplant recipients: mTOR inhibitors everolimus and sirolimus are not peas from a pod. Am J Transplant. 2013 Jul; 13(7):1633-5.
    View in: PubMed
    Score: 0.258
  31. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant. 2013 Jun; 18(3):251-8.
    View in: PubMed
    Score: 0.256
  32. Interleukin-28B polymorphism in hepatitis C and liver transplantation. Liver Transpl. 2013 Jan; 19(1):49-58.
    View in: PubMed
    Score: 0.249
  33. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012 Sep; 18(9):1029-36.
    View in: PubMed
    Score: 0.243
  34. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation. 2012 Jul 27; 94(2):197-203.
    View in: PubMed
    Score: 0.242
  35. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl. 2012 Jul; 18(7):803-10.
    View in: PubMed
    Score: 0.241
  36. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012 Mar; 18(3):323-31.
    View in: PubMed
    Score: 0.235
  37. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant. 2012 Mar; 12(3):737-44.
    View in: PubMed
    Score: 0.234
  38. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011 Oct; 141(4):1249-53.
    View in: PubMed
    Score: 0.224
  39. Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay. Liver Transpl. 2011 Jun; 17(6):723-32.
    View in: PubMed
    Score: 0.223
  40. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011 Jan; 53(1):317-24.
    View in: PubMed
    Score: 0.217
  41. Posttransplant metabolic syndrome: new evidence of an epidemic and recommendations for management. Liver Transpl. 2011 Jan; 17(1):1-6.
    View in: PubMed
    Score: 0.217
  42. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl. 2011 Jan; 17(1):23-31.
    View in: PubMed
    Score: 0.217
  43. Pretransplant serum troponin levels are highly predictive of patient and graft survival following liver transplantation. Liver Transpl. 2010 Aug; 16(8):990-8.
    View in: PubMed
    Score: 0.211
  44. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010 Jun; 10(6):1420-7.
    View in: PubMed
    Score: 0.207
  45. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010 Jul; 53(1):199-206.
    View in: PubMed
    Score: 0.206
  46. Antibody-based immunosuppression following liver transplantation: the plot thickens. Am J Transplant. 2010 Mar; 10(3):445-6.
    View in: PubMed
    Score: 0.204
  47. Fatty liver and liver transplantation. Clin Liver Dis. 2009 Nov; 13(4):621-30.
    View in: PubMed
    Score: 0.200
  48. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl. 2009 Nov; 15 Suppl 2:S83-9.
    View in: PubMed
    Score: 0.200
  49. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl. 2009 Nov; 15(11):S1-34.
    View in: PubMed
    Score: 0.200
  50. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009 Aug; 9(8):1707-13.
    View in: PubMed
    Score: 0.195
  51. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009 Jun; 9(6):1406-13.
    View in: PubMed
    Score: 0.194
  52. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008 Nov; 8(11):2426-33.
    View in: PubMed
    Score: 0.184
  53. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant. 2008 Mar; 8(3):667-72.
    View in: PubMed
    Score: 0.178
  54. Approach to recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep. 2007 Mar; 9(1):23-30.
    View in: PubMed
    Score: 0.166
  55. Perioperative viral kinetics: new insights or the Emperor's new clothes? Liver Transpl. 2006 Feb; 12(2):194-5.
    View in: PubMed
    Score: 0.154
  56. Recurrence of hepatitis C infection: Where are we now? Liver Transpl. 2005 Nov; (11 Suppl 2):S57-62.
    View in: PubMed
    Score: 0.152
  57. Retransplantation for HCV--the view through a broken crystal ball. Liver Transpl. 2005 Apr; 11(4):382-3.
    View in: PubMed
    Score: 0.146
  58. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 2004 Sep; 10(9):1120-30.
    View in: PubMed
    Score: 0.140
  59. Obesity in potential living donors: success with simplicity. Liver Transpl. 2004 Jun; 10(6):726-7.
    View in: PubMed
    Score: 0.137
  60. Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis. 2004; 24 Suppl 2:79-88.
    View in: PubMed
    Score: 0.133
  61. Management of recurrence of hepatitis C infection following liver transplantation. Minerva Chir. 2003 Oct; 58(5):717-24.
    View in: PubMed
    Score: 0.131
  62. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis. 2003 Aug; 7(3):585-602.
    View in: PubMed
    Score: 0.130
  63. Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am J Transplant. 2003 Jul; 3(7):885-90.
    View in: PubMed
    Score: 0.129
  64. The impact of advancing donor age on histologic recurrence of hepatitis C infection: the perils of ignored maternal advice. Liver Transpl. 2003 May; 9(5):535-7.
    View in: PubMed
    Score: 0.127
  65. Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol. 2023 07; 21(8):2150-2166.
    View in: PubMed
    Score: 0.127
  66. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl. 2002 Sep; 8(9):814-21.
    View in: PubMed
    Score: 0.122
  67. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002 Jul; 8(7):623-9.
    View in: PubMed
    Score: 0.120
  68. Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States. Transplantation. 2022 10 01; 106(10):2006-2018.
    View in: PubMed
    Score: 0.120
  69. Preservation solutions for static cold storage in donation after circulatory death and donation after brain death liver transplantation in the United States. Liver Transpl. 2022 09; 28(9):1454-1462.
    View in: PubMed
    Score: 0.119
  70. Patient and graft survival following liver transplantation for hepatitis C: much ado about something. Gastroenterology. 2002 Apr; 122(4):1162-5.
    View in: PubMed
    Score: 0.118
  71. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002 Apr; 8(4):350-5.
    View in: PubMed
    Score: 0.118
  72. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl. 2002 Apr; 8(4):362-9.
    View in: PubMed
    Score: 0.118
  73. Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire? Liver Transpl. 2002 Jan; 8(1):47-9.
    View in: PubMed
    Score: 0.116
  74. Hepatitis C infection in liver transplantation. Am J Transplant. 2001 Sep; 1(3):197-203.
    View in: PubMed
    Score: 0.114
  75. Simultaneous Heart-Liver Transplantation for Congenital Heart Disease in the United States: Rapidly Increasing With Acceptable Outcomes. Hepatology. 2021 04; 73(4):1464-1477.
    View in: PubMed
    Score: 0.110
  76. Impact of nutritional status on outcomes after liver transplantation. Transplantation. 2000 Nov 15; 70(9):1347-52.
    View in: PubMed
    Score: 0.107
  77. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology. 2000 Nov; 32(5):1125-30.
    View in: PubMed
    Score: 0.107
  78. Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency. Am J Transplant. 2021 03; 21(3):1039-1055.
    View in: PubMed
    Score: 0.106
  79. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation. 2000 Jul 27; 70(2):292-7.
    View in: PubMed
    Score: 0.105
  80. Genotype 1b and severity of posttransplant recurrence of hepatitis C infection- unconvictable felon or wrongly accused? Liver Transpl. 2000 Mar; 6(2):243-5.
    View in: PubMed
    Score: 0.102
  81. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg. 1999 Jul; 5(4 Suppl 1):S107-14.
    View in: PubMed
    Score: 0.098
  82. Simultaneous heart, liver and kidney transplantation: A viable option for heart failure patients with multiorgan failure. J Heart Lung Transplant. 2019 09; 38(9):997-999.
    View in: PubMed
    Score: 0.097
  83. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors. Hepatology. 2019 06; 69(6):2381-2395.
    View in: PubMed
    Score: 0.096
  84. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transpl. 2019 04; 25(4):598-609.
    View in: PubMed
    Score: 0.096
  85. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998 Sep; 28(3):823-30.
    View in: PubMed
    Score: 0.092
  86. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol. 2018 Mar 28; 24(12):1321-1331.
    View in: PubMed
    Score: 0.090
  87. Hepatitis G virus infection in patients transplanted for cryptogenic cirrhosis: red flag or red herring? Transplantation. 1998 Jan 15; 65(1):73-6.
    View in: PubMed
    Score: 0.088
  88. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg. 1997 Jul; 3(4):359-64.
    View in: PubMed
    Score: 0.085
  89. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017 05; 101(5):945-955.
    View in: PubMed
    Score: 0.084
  90. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation. 2017 05; 101(5):956-967.
    View in: PubMed
    Score: 0.084
  91. Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. Gastroenterology. 2016 10; 151(4):633-636.e3.
    View in: PubMed
    Score: 0.079
  92. Protecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 2016 09; 16(9):2516-31.
    View in: PubMed
    Score: 0.079
  93. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
    View in: PubMed
    Score: 0.073
  94. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015 May; 21(5):599-606.
    View in: PubMed
    Score: 0.073
  95. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015 May; 61(5):1485-94.
    View in: PubMed
    Score: 0.073
  96. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl. 2015 Feb; 21(2):248-57.
    View in: PubMed
    Score: 0.072
  97. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int. 2014 Sep; 34(8):1259-66.
    View in: PubMed
    Score: 0.066
  98. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl. 2013 Aug; 19(8):887-95.
    View in: PubMed
    Score: 0.065
  99. Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transpl Int. 2013 Aug; 26(8):788-94.
    View in: PubMed
    Score: 0.064
  100. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013 Feb; 13(2):363-8.
    View in: PubMed
    Score: 0.062
  101. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
    View in: PubMed
    Score: 0.058
  102. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology. 2011 Jul; 54(1):3-5.
    View in: PubMed
    Score: 0.056
  103. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011 May; 17(5):528-38.
    View in: PubMed
    Score: 0.055
  104. Daclizumab induction therapy in liver transplant recipients with renal insufficiency. Aliment Pharmacol Ther. 2010 Sep; 32(6):776-86.
    View in: PubMed
    Score: 0.053
  105. Combined heart and liver transplantation: a single-center experience. Transplantation. 2009 Jul 27; 88(2):219-25.
    View in: PubMed
    Score: 0.049
  106. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007 Sep; 13(9):1246-53.
    View in: PubMed
    Score: 0.043
  107. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation. 2007 Jun 27; 83(12):1639-42.
    View in: PubMed
    Score: 0.042
  108. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 2006 Sep; 12(9):1381-9.
    View in: PubMed
    Score: 0.040
  109. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2005 Oct; 11(10):1207-13.
    View in: PubMed
    Score: 0.038
  110. Hypophosphatemia after right hepatectomy for living donor liver transplantation. Can J Gastroenterol. 2004 Dec; 18(12):729-33.
    View in: PubMed
    Score: 0.036
  111. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004 Dec; 2(12):1048-58.
    View in: PubMed
    Score: 0.036
  112. Pre-emptive treatment of recurrent hepatitis C infection. Liver Transpl. 2002 Oct; 8(10 Suppl 1):S50-4.
    View in: PubMed
    Score: 0.031
  113. Origin of adenocarcinoma in a transplanted liver determined by microsatellite analysis. Hum Pathol. 2002 Apr; 33(4):435-6.
    View in: PubMed
    Score: 0.030
  114. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 2001 Jul; 7(7):608-14.
    View in: PubMed
    Score: 0.028
  115. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001 Apr; 7(4):302-10.
    View in: PubMed
    Score: 0.028
  116. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol. 2000 Mar; 13(3):229-37.
    View in: PubMed
    Score: 0.026
  117. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. 1999 Nov; 30(5):1121-7.
    View in: PubMed
    Score: 0.025
  118. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999 Apr; 29(4):1050-6.
    View in: PubMed
    Score: 0.024
  119. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology. 1999 Apr; 29(4):1220-6.
    View in: PubMed
    Score: 0.024
  120. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018 07; 68(1):361-371.
    View in: PubMed
    Score: 0.023
  121. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 01; 67(1):328-357.
    View in: PubMed
    Score: 0.022
  122. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
    View in: PubMed
    Score: 0.019
  123. Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infect Dis. 2015 Sep 02; 15:371.
    View in: PubMed
    Score: 0.019
  124. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013 Jul; 19(7):690-700.
    View in: PubMed
    Score: 0.016
  125. Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. Am J Transplant. 2003 Jun; 3(6):743-53.
    View in: PubMed
    Score: 0.008
  126. The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Apr; 94(4):1000-5.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.